News

FlAIR Trial 2018 update

This trial is comparing ibrutinib alongside rituximab with fludarabine, cyclophosphamide, rituximab and venetoclax for chronic lymphocytic leukaemia. This trial is for people who haven’t yet had treatment for their chronic lymphocytic leukaemia (CLL). The CLLSA supports this research.

The Flair Trial researchers think that ibrutinib with rituximab, or venetoclax, might work well for people with CLL who haven’t yet had treatment. To find this out they want to compare:

fludarabine, cyclophosphamide and rituximab (FCR)

FLAIR Trial

This trial is comparing ibrutinib alongside rituximab with fludarabine, cyclophosphamide, rituximab and venetoclax for chronic lymphocytic leukaemia. This trial is for people who haven’t yet had treatment for their chronic lymphocytic leukaemia (CLL). The CLLSA supports this research.

 

The Flair Trial researchers think that ibrutinib with rituximab, or venetoclax, might work well for people with CLL who haven’t yet had treatment. To find this out they want to compare:

Bristol Members Conference 20 Jul 2018 videos available

The meeting summary together with the videos and slides of the main presentations by Prof Chris Fegan and Dr Stephen Man are now available here

Prof Chris Fegan talked to “CLL treatment – who needs treatment and how do we move from where we are to cure?” 

Dr Stephen Man talked about his research into T cells 

The photo shows Olga Janssen Prof Chris Fegan and Dr Stephen Man on the roof of the venue 'We the curious' in Bristol.